CONSUMENTENBOND
On Friday October 6, 2023, the Sub-District Court of Oost-Brabant (‘s-Hertogenbosch) ruled that Volkswagen must compensate yet another Dutch Dieselgate consumer who purchased a VW vehicle containing illegal defeat device software. The Court ruled that Volkswagen must pay €4440 - the equivalent of 10% of the vehicle’s purchase price.
This is the latest of four lawsuits brought by the Volkswagen Group Diesel Efficiency Foundation (VGDES) (a Dutch organization representing consumer rights) and Consumentenbond (the Dutch consumer rights organization) on behalf of consumers defrauded by VW. Earlier this year, in March, April and July 2023, other Dutch courts all ruled against Volkswagen finding that it must pay damages to Dutch consumers who similarly purchased vehicles equipped with illegal software. In those prior rulings, the courts awarded €3,000 for an impacted new VW diesel vehicle and €1,500 for a used one. In this latest opinion, the judge increased the penalty finding that those amounts were too low, and determining that the appropriate sanction was a percentage of the vehicle’s purchase price.
A Fourth Defeat for Volkswagen
“This is the fourth time in a row that the Court has ruled against Volkswagen,” said Dick Bouma, chairman of VGDES. “The judge swept aside all VW’s technical legal defenses, and simply found that the car maker deceived consumers. Courts here and all over the world have determined that the company has deliberately misled consumers, including by promoting these diesel cars as environmentally friendly. It is time for Volkswagen to compensate harmed consumers.”
Volkswagen Should Resolve the Claims of the Hundreds of Thousands Dutch Consumers
Sandra Molenaar, Consumentenbond CEO, is pleased with the ruling and looks ahead: “So far we have won all four lawsuits against VW concerning its illegal use of defeat device software in diesel cars. Following this even stronger decision, we again invite Volkswagen to engage in settlement talks. Hopefully, the company is now prepared to compensate all affected Dutch consumers. If not, there are thousands of individual cases we can file against the Company. And, if necessary, we will take each and every case to court to hold Volkswagen accountable and to force the Company to compensate all impacted consumers.”
Links
- March: https://www.consumentenbond.nl/nieuws/2023/doorbraak-in-volkswagen-dieselschandaal-rechter-wijst-compensatie-toe
- April: https://www.consumentenbond.nl/nieuws/2023/weer-succes-in-rechtszaak-om-volkswagen-sjoemeldiesel
- July: https://www.consumentenbond.nl/nieuws/2023/volkswagen-moet-eigenaar-tweedehands-sjoemeldiesel-1500euro-betalen
- October: https://www.consumentenbond.nl/nieuws/2023/volkswagen-opnieuw-veroordeeld-in-dieselgate-procedure
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231011132017/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release
Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom